Lymphoma, Follicular Clinical Trial
Official title:
A Randomized, Double-blind, Parallel-arm, Phase I Study to Evaluate the Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab (MabThera) Induction Immunotherapy as a First-line Treatment in Patients With Low Tumor Burden Follicular Lymphoma
Verified date | August 2018 |
Source | Boehringer Ingelheim |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objective of the study is to assess the pharmacokinetic (PK) similarity of
Boehringer Ingelheim (BI) 695500 vs. rituximab (MabThera®) in previously untreated patients
with low tumor burden follicular lymphoma (LTBFL).
The secondary objective of the study is to evaluate the pharmacodynamics (PD), safety, and
anti-tumor activity of BI 695500 vs. rituximab (MabThera®), as well as the presence of
anti-drug antibodies (ADAs).
Status | Completed |
Enrollment | 95 |
Est. completion date | December 22, 2015 |
Est. primary completion date | December 22, 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion criteria: - Must give written informed consent and be willing to follow this Clinical Trial Protocol. - Male or female patients, at least 18 years of age at Screening. - Histologically-confirmed, stage II - IV Non-Hodgkin's lymphoma (CD20+ FL of Grades 1, 2, or 3a). - Low tumor burden according to the Groupe d'Etudes des Lymphomes Folliculaires (GELF) criteria - no nodal or extranodal involvement of more than 7 cm, no more than 3 nodal sites with a diameter >3 cm, no B symptoms (i.e., fever >38°C, weight loss - unexplained loss of >10 % body weight over the past 6 months, and sweats - the presence of drenching night sweats), no significant splenomegaly, no significant serious effusion, no complications such as organ compression, and less than 5x10^9/L circulating tumor cells. - Availability of archived tumor sample prior to screening. - Patients not previously treated for their FL. - Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. - Have at least 1 measurable lesion as per the International Working Group (IWG) criteria 2007 at Screening (lesion clearly measurable in at least 2 perpendicular dimensions; see Appendix 10.1 for further details). - Adequate hematological function (unless abnormalities are related to lymphoma infiltration of the bone marrow) within 28 days prior to randomization, including: - - hemoglobin =9.0 g/dL (=5.6 mmol/L). - - absolute neutrophil count =1.5 × 10^9/L. - - platelet count =100 × 10^9/L. - Adequate renal and liver function: - - serum creatinine <2.0 mg/dL (<176.8 micromol/L). - - total bilirubin <2.0 mg/dL (<34 mcmol/L) except for patient with Gilbert's Syndrome or Hemolysis. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <3 x upper limit of normal (ULN) (<5 x ULN is acceptable if abnormalities are thought to be related to hepatic infiltration by FL). - For participants of reproductive potential (males and females), use of a medically acceptable method of contraception during the trial, i.e., a combination of 2 forms of effective contraception (defined as hormonal contraception, intrauterine device, condom with spermicide, etc.). Females of childbearing potential (includes tubal ligation) and males with female partners of childbearing potential must also agree to use an acceptable method of contraception (see above) for 12 months following completion or discontinuation from the trial medication. Exclusion criteria: - Transformation to high-grade lymphoma (secondary to low-grade lymphoma). - Presence or history of central nervous system lymphoma. - Patients receiving current treatment with corticosteroids must not be receiving a dose exceeding 20 mg/day prednisone or equivalent. - Patients with prior or concomitant malignancies within 5 years prior to screening except non-melanoma skin cancer, adequately treated carcinoma in situ of the cervix, adequately treated breast cancer in situ, localized prostate cancer stage T1c - provided that the patient underwent curative treatment, and remains relapse free. - Major surgery (excluding lymph node biopsy) within 28 days prior to randomization. - Active, chronic or persistent infection that might worsen with immunosuppressive treatment (e.g., Human Immunodeficiency Virus [HIV], Hepatitis C Virus [HCV], Herpes Zoster); positive for HIV or tuberculosis at Screening. - Patients with serological evidence of Hepatitis B virus (HBV) infection. Patients seropositive because of HBV vaccine are eligible. HBV positive patients may participate following consultation with a hepatitis expert regarding monitoring and use of HBV antiviral therapy, and provided they agree to receive treatment as indicated. - Serious underlying medical conditions, which, per the investigator's discretion, could impair the ability of the patient to participate in the trial (including but not limited to ongoing active infection, severe immunosuppression, uncontrolled diabetes mellitus, gastric ulcers, active autoimmune disease); patients who have significant cardiac disease, including but not limited to congestive heart failure of Class III or IV of the NYHA classification; uncontrolled angina or arrhythmia; any uncontrolled or severe cardiovascular or cerebrovascular disease. - Known hypersensitivity or allergy to murine products. - History of a severe allergic reaction or anaphylactic reaction to a biological agent or history of hypersensitivity to any component of the trial drug. - Receipt of a live/attenuated vaccine within 12 weeks prior to the Screening Visit. - Prior treatment with BI 695500 and/or rituximab. - Patients who received any prior therapy using monoclonal antibodies will be excluded; this does not apply to other biological drugs such as growth factors or anticoagulants. - Treatment within a clinical trial within 4 weeks prior to initiation of trial treatment. Patients who have received treatment with a drug that has not received regulatory approval for any indication within 4 weeks or a minimum of 5 half-lives, whichever is longer, of the initial dose of trial medication. - Any other co-existing medical or psychological condition(s) that will preclude participation in the trial or compromise ability to give informed consent and/or comply with study procedures. - Pregnancy or breast feeding. For women of childbearing potential, a positive serum pregnancy test at the Screening Visit. - Patients who have significant cardiac disease, including but not limited to congestive heart failure of Class III or IV of the New York Heart Association (NYHA) classification; uncontrolled angina or arrhythmia; any uncontrolled or severe cardiovascular or cerebrovascular disease; or uncontrolled hypertension. |
Country | Name | City | State |
---|---|---|---|
Australia | The Canberra Hospital | Canberra | Migration Data |
Austria | AKH - Medical University of Vienna | Wien | |
Belgium | Brussels - UNIV St-Luc | Bruxelles | |
Belgium | UZ Leuven | Leuven | |
Belgium | Namur - HOSP Ste-Elisabeth | Namur | |
Croatia | Clinical Hospital Centre Zagreb | Zagreb | |
Czechia | University Hospital Brno | Brno | |
Czechia | University Hospital Ostrava | Ostrava-Poruba | |
Czechia | Vseobecna fakultni nemocnice V Praze | Praha 2 | |
France | INS Bergonié | Bordeaux cedex | |
France | HOP Morvan | Brest | |
France | Centre Hospitalier Départemental Les Oudairies | La Roche sur Yon | |
France | HOP Haut-Lévêque | Pessac | |
France | Hôpital la Milétrie - CHU Poitiers | Poitiers | |
Germany | Gesundheitszentrum Wetterau gGmbH | Bad Nauheim | |
Germany | Universitätsklinikum Carl Gustav Carus Dresden | Dresden | |
Germany | Universitätsklinikum Freiburg | Freiburg | |
Germany | Haemato-Onkologie Hamburg | Hamburg | |
Germany | Klinikum Kassel GmbH | Kassel | |
Greece | General Hospital of Athens "G. Gennimatas" | Athens | |
Hungary | Semmelweis University, 1st Dept. Internal Medicine | Budapest | |
New Zealand | Auckland Clinical Studies Ltd | Auckland | |
Poland | Oncol Centre M Sklodowska-Curie, Dept of Lung & Chest Cancer | Warszawa | |
Russian Federation | BHI of Omsk region - Clinical Oncology Dispensary | Omsk | |
Russian Federation | St. Petersburg GUZ City Clinical Oncology Dispensary | St. Petersburg | |
Spain | Hospital Germans Trias i Pujol | Badalona | |
Spain | Hospital Puerta del Mar | Cádiz | |
Spain | Fundación Jiménez Díaz | Madrid | |
Spain | Hospital Virgen del Rocío | Sevilla |
Lead Sponsor | Collaborator |
---|---|
Boehringer Ingelheim |
Australia, Austria, Belgium, Croatia, Czechia, France, Germany, Greece, Hungary, New Zealand, Poland, Russian Federation, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Area Under the Concentration (AUC) Time Curve of BI 695500 and Rituximab (MabThera®) Over the First Dosing Interval (Pre-infusion on Day 1 to Pre-infusion on Day 8) | This outcome measure presents area under the concentration time curve of BI 695500 and Rituximab (MabThera®) over the first dosing interval (pre-infusion on Day 1 to pre-infusion on Day 8) (AUCDay 1-Day 8) for assessment of PK (Pharmacokinetics) similarity. | Blood samplings were done at pre-infusion and at end of infusion at 1, 2, and 4 hours from end of infusion 1, and at 24, 48, 72, 96 and 168 hours from start of infusion 1. | |
Secondary | AUC of BI 695500 and Rituximab (MabThera®) Over the Fourth Dosing Interval (Pre-infusion on Day 22 to Day 29) (AUC Day 22-Day 29) | This outcome measure presents area under the concentration of BI 695500 and Rituximab (MabThera®) over the fourth dosing interval (pre-infusion on Day 22 to Day 29). | Blood samplings were done at pre-infusion and at end of infusion at 1, 2, and 4 hours from end of infusion 4, and at 24, 48, 72, 96 and 168 hours from start of infusion 4. | |
Secondary | Maximum Measured Concentration of BI 695500 and Rituximab (MabThera®) in Plasma (Cmax) Following Dose 1 | This outcome measure presents maximum measured concentration of BI 695500 and Rituximab (MabThera®) in plasma (Cmax) following Dose 1 | Blood samplings were done at pre-infusion and at end of infusion at 1, 2, and 4 hours from end of infusion 1, and at 24, 48, 72, 96 and 168 hours from start of infusion 1. | |
Secondary | Maximum Measured Concentration of Rituximab (MabThera®) and BI 695500 in Plasma (Cmax) Following Dose 4 | This outcome measure presents maximum measured concentration of Rituximab (MabThera®) and BI 695500 in plasma (Cmax) following Dose 4. | Blood samplings were done at pre-infusion and at end of infusion at 1, 2, and 4 hours from end of infusion 4, and at 24, 48, 72, 96, 168, 336, 672, 1344, 2016 and 2880 hours from start of infusion 4. | |
Secondary | Area Under the Depletion-time Curve of the Cluster of Differentiation (CD)19+ B-cell Count (% Change From Baseline (CFB)) in Peripheral Blood From Pre-infusion on Day 1 Until Last Measurement on Day 8 (Pre-infusion) | This outcome measure presents area under the depletion-time curve of the CD19+ B-cell count (% change from baseline) in peripheral blood from pre-infusion on Day 1 until last measurement on Day 8 (pre-infusion) (AUC Day 1-Day 8, CD19+). | Blood samplings were done at pre-infusion and at end of infusion at 1, 2, and 4 hours from end of infusion, and at 24, 48, 72, 96 and 168 hours from start of infusion. | |
Secondary | Change From Baseline (%) of CD19+ B-cells in Peripheral Blood Measured After Seven Days on Day 8 (Day 8 Pre-infusion Time Point) | This outcome measure presents percent change from baseline of CD19+ B-cells in peripheral blood, measured after 7 days (i.e., Day 8 pre-infusion time point) (PCFBpre,2 CD19+). | Blood sampling was done at 168 hours from start of infusion. | |
Secondary | Overall Response Rate (ORR) (Complete Response (CR) Plus Partial Response (PR)) Evaluated Approximately One Month After Last Dose of BI 695500 or Rituximab (MabThera®) | Overall Response Rate (ORR) comprised Complete Response (CR) plus Partial Response (PR) evaluated approximately one month after last dose of BI 695500 or Rituximab [MabThera®]. Overall Response as defined by the revised International Working Group (IWG) Criteria 2007, using the Investigator's assessment. | at Day 50. | |
Secondary | Percentage of Patients With Treatment Emergent Adverse Events (TEAEs) Selected for Comparability Assessment of BI 695500 and Rituximab (MabThera®) | This outcome measure presents percentage of patients with Treatment Emergent Adverse Events (TEAEs) selected for comparability assessment of BI 695500 and Rituximab (MabThera®). | Adverse Events (AEs) that started or worsened on or after the first dose of study medication and prior to the last date of study medication + 4 months (120 days) inclusive. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00930514 -
A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma
|
Phase 1 | |
Completed |
NCT02472756 -
Open, Noninterventional Trial of MabThera in Combination With Chemotherapy (CVP, CHOP or FCM) in Patients With Relapsed/Refractory Follicular Lymphoma
|
N/A | |
Withdrawn |
NCT00319332 -
A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen
|
Phase 3 | |
Completed |
NCT00193492 -
A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma
|
Phase 2 | |
Withdrawn |
NCT00092274 -
Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT03087929 -
Follow-up Trial of Rituximab Interferon Transplant Trial: Study Drug-Rituximab and Alpha Interferon
|
N/A | |
Terminated |
NCT02413489 -
An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
|
Phase 2 | |
Completed |
NCT00915096 -
Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma
|
||
Recruiting |
NCT05849857 -
Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries
|
Phase 2 | |
Recruiting |
NCT05410418 -
Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
|
Phase 2 | |
Terminated |
NCT01609036 -
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma
|
N/A | |
Completed |
NCT01234766 -
Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma
|
Phase 2 | |
Completed |
NCT00849147 -
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
|
Phase 2 | |
Terminated |
NCT00384111 -
Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)
|
Phase 3 | |
Completed |
NCT03682796 -
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma
|
Phase 1 | |
Recruiting |
NCT04982471 -
Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
|
||
Active, not recruiting |
NCT02996773 -
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
|
Phase 1 | |
Terminated |
NCT00562965 -
Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)
|
Phase 3 | |
Active, not recruiting |
NCT00317096 -
FCM Versus R-FCM Followed by R-Maintenance or Observation Only
|
Phase 3 | |
Not yet recruiting |
NCT06213636 -
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
|
Phase 1/Phase 2 |